Damora Therapeutics Inc (DMRA) FinancialsDMRADamora Therapeutics Inc

Evaluating the bottom line, Damora Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -132.85%, provide a clear picture of how effectively DMRA converts its operational activities into shareholder value.

In the context of the broader market, DMRA competes directly with industry leaders such as NBTX and ETON. With a market capitalization of $1.89B, it holds a significant position in the sector. When comparing efficiency, DMRA's gross margin of N/A stands against NBTX's 100.00% and ETON's 67.61%. Such benchmarking helps identify whether Damora Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown a significant cash reserve of $532.9 million, which provides a buffer against its ongoing losses, including a net loss of $27.8 million in the latest quarter. The current ratio is strong at 19.73, indicating good short-term financial health.